Publication | Closed Access
Omalizumab therapy for chronic spontaneous urticaria: the Israeli experience.
15
Citations
17
References
2014
Year
Omalizumab is an effective and safe treatment for refractory CSU with rapid onset of action for inducing and maintaining remission. Treating CSU patients mandates an individual approach, because while low dose omalizumab will suffice for some patients others might need higher doses and prolonged therapy.
| Year | Citations | |
|---|---|---|
Page 1
Page 1